The drug was approved by the U.S. Food and Drug Administration in November 2017.
Dr. Cynthia Dunbar, of the NIH, talks about the “critical mass of successes” in hematology and what is coming in the future.
From the Journals
The phase 2 trial included patients who did not respond to erythropoiesis-stimulating agents.
Eltrombopag, from Novartis, will get expedited review for first-line treatment of severe aplastic anemia. It is already approved as a second-line...
ATLANTA – Successfully treating Waldenström macroglobulinemia often resolves acquired von Willebrand disease.
The newly cleared software is designed for use in developing personalized prophylaxis regimens for patients with hemophilia A.
The newly-cleared software is designed for use in developing personalized prophylaxis regimens for patients with hemophilia A.
ATLANTA – Phase 2 data on aTTP earned caplacizumab an FDA fast track designation in July 2017.
ATLANTA – Intrabone gene therapy could offer long-term hope for patients with beta-thalassemia who cannot be treated by allogeneic HSCT.
ATLANTA – Gene therapy is “holy grail” for managing hemophilia – a single-gene disorder with a clear relationship between clotting factor level...